Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/04/26
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/02/26
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/05/26
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh CatalystZacks Investment Research • 05/27/26
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to KnowZacks Investment Research • 05/27/26
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/22/26
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 StudyMarketBeat • 05/21/26
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical MutationsGlobeNewsWire • 05/21/26
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLCGlobeNewsWire • 05/19/26
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/07/26
Implied Volatility Surging for Black Diamond Therapeutics Stock OptionsZacks Investment Research • 04/28/26
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go RightZacks Investment Research • 04/23/26
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and RisksZacks Investment Research • 04/23/26
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual MeetingGlobeNewsWire • 04/21/26
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See OpportunitySeeking Alpha • 03/25/26
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/16/26